Amgen Inc Gets a Hold Rating from Barclays

By Jason Carr

In a report released today, Geoff Meacham from Barclays maintained a Hold rating on Amgen Inc (NASDAQ: AMGN), with a price target of $190. The company’s shares opened today at $182.64, close to its 52-week high of $191.10.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 8.4% and a 57.0% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Amgen Inc is Moderate Buy and the average price target is $192.50, representing a 5.4% upside.

In a report issued on October 4, Robert W. Baird also reiterated a Hold rating on the stock with a $165 price target.

Amgen Inc’s market cap is currently $133.5B and has a P/E ratio of 16.66. The company has a book value ratio of 4.2098.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.